Background:
Early prediction of outcome in patients with malignant
middle cerebral artery infarction may help the proper choice for the
therapeutic decision in this stroke subtype. Objective:
We attempted to investigate the possible role of serum S100
B protein, beside other clinical and radiological determinants, in prediction
of outcome of malignant cerebral infarction. Methods:
This study was conducted on 42 stroke patients with
clinical and radiological evidence of malignant cerebral infarction (group I),
and 20 patients with non malignant cerebral infarction as a morbid control
(group II), in addition to 20 individuals as a healthy control (group III).
Assessment of the disability was done by modified Rankin Scale, which was
performed after one week, then after one month and after three months of
admission. Computerized tomography of the brain was done for all patients on
admission, and was repeated after one week for group I patients. Serum S100 B
protein was measured initially for the three groups and after one week for
group I patients. Results: the
serum S100B protein value on admission was significantly higher in group I
patients when compared to both group II and group III patients.
Follow up values were increased but without significant difference from the
initial values in group I patients. Moreover, the S100B value was significantly
related to the mortality outcome. Conclusion:
Serum S100B protein on admission (beside other clinical and radiological
predictors) can predict the outcome of malignant middle cerebral artery
infarction. [Egypt J Neurol Psychiat
Neurosurg. 2012; 49(2): 157-164]
Key words: Malignant infarction, Middle cerebral artery, Serum S100B.
Correspondence to Dr Ashraf A. Aboelsafa,
Neuropsychiatry Department, Tanta University; Egypt.
Tel: +20106622792. E-mail:
draboelsafa@hotmail.com.